Piramal Pharma Limited Share Price Today - Piramal Pharma Limited Stock Price Live NSE/BSE

Piramal Pharma Limited stock performance

Today’s low

209.26

Today’s high

216.37

211.05

52 week low

136.1

52 week high

307.9

211.05

Open

212.0

Previous close

211.96

Share volume

3050996.0

Total traded value (Lakh)

6439.12

Upper circuit

254.35

Lower circuit

169.56

Piramal Pharma Limited fundamentals

Market cap (Cr)

27920.82

P/E ratio (TTM)

40.74

Book value per share

₹ 0.0

Beta

0.82

Return on equity

6.53

Earnings per share (TTM)

₹ 5.18

Dividend yield

0.05%

Net profit/quarter (Cr)

₹ 118.8

Piramal Pharma Limited financials

(Values in Cr)

Revenue

Net income

Revenue
Particulars	202412 (₹ value in crores)
Revenue	1248.32
Operating expense	1113.61
Net income	118.8
Net profit margin	9.51%
Earnings per share	0.9
EBITDA	244.04
Effective tax rate	25.47

Revenue
Particulars	202409 (₹ value in crores)
Revenue	1284.39
Operating expense	1115.06
Net income	210.06
Net profit margin	16.35%
Earnings per share	1.59
EBITDA	359.27
Effective tax rate	23.81

Revenue
Particulars	202406 (₹ value in crores)
Revenue	1063.2
Operating expense	988.3
Net income	85.27
Net profit margin	8.02%
Earnings per share	0.64
EBITDA	188.39
Effective tax rate	23.63

Revenue
Particulars	202403 (₹ value in crores)
Revenue	1525.3
Operating expense	1215.82
Net income	273.08
Net profit margin	17.9%
Earnings per share	2.06
EBITDA	442.83
Effective tax rate	24.7

Revenue
Particulars	202312 (₹ value in crores)
Revenue	1024.14
Operating expense	967.58
Net income	74.34
Net profit margin	7.25%
Earnings per share	0.56
EBITDA	158.64
Effective tax rate	17.08

(Values in Cr)

Revenue

Net income

Revenue Annual
Particulars	202403 (₹ value in crores)
Revenue	4390.11
Operating expense	4084.54
Net income	391.22
Net profit margin	8.91%
Earnings per share	3.05
EBITDA	819.98
Effective tax rate	22.93

Revenue Annual
Particulars	202303 (₹ value in crores)
Revenue	3443.22
Operating expense	3653.64
Net income	69.5
Net profit margin	2.01%
Earnings per share	0.58
EBITDA	431.64
Effective tax rate	43.81

Revenue Annual
Particulars	202203 (₹ value in crores)
Revenue	3340.42
Operating expense	3087.8
Net income	367.54
Net profit margin	11.0%
Earnings per share	3.12
EBITDA	684.99
Effective tax rate	20.5

ROE

ROCE

Consolidated Ratios
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	59.8
Return on Equity (ROE)	0.22
Return on Capital Employed (ROCE)	5.4
Total debt to equity ratio	0.7
EBITDA margin	17.47

Consolidated Ratios
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	56.76
Return on Equity (ROE)	-2.77
Return on Capital Employed (ROCE)	1.9
Total debt to equity ratio	0.72
EBITDA margin	12.72

Consolidated Ratios
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	56.47
Return on Equity (ROE)	6.11
Return on Capital Employed (ROCE)	6.91
Total debt to equity ratio	0.58
EBITDA margin	19.35

Consolidated Ratios
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	56.35
Return on Equity (ROE)	14.9
Return on Capital Employed (ROCE)	12.67
Total debt to equity ratio	0.54
EBITDA margin	26.25

ROE

ROCE

Satandalone Data
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	50.74
Return on Equity (ROE)	6.53
Return on Capital Employed (ROCE)	8.27
Total debt to equity ratio	0.24
EBITDA margin	18.68

Satandalone Data
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	44.09
Return on Equity (ROE)	1.34
Return on Capital Employed (ROCE)	3.62
Total debt to equity ratio	0.27
EBITDA margin	12.54

Satandalone Data
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	43.2
Return on Equity (ROE)	7.97
Return on Capital Employed (ROCE)	9.82
Total debt to equity ratio	0.15
EBITDA margin	20.51

Satandalone Data
Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	41.23
Return on Equity (ROE)	13.94
Return on Capital Employed (ROCE)	16.15
Total debt to equity ratio	0.04
EBITDA margin	28.42

(Values in Cr)

Consolidated Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	482.56
	15311.81
	15311.81
Total Equity	7911.37
Shares Outstanding	1322948130
Price to book ratio	2.54
Return on assets (%)	0.11
Return on capital (%)	0.14

Consolidated Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	307.56
	14522.56
	14522.56
Total Equity	6773.5
Shares Outstanding	1193318500
Price to book ratio	1.55
Return on assets (%)	-1.28
Return on capital (%)	-1.52

Consolidated Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	328.99
	12797.04
	12797.04
Total Equity	6696.6
Shares Outstanding	1185913506
Price to book ratio	0.0
Return on assets (%)	2.93
Return on capital (%)	3.51

Consolidated Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	405.62
	10899.78
	10899.78
Total Equity	5605.0
Shares Outstanding	994600000
Price to book ratio	0.0
Return on assets (%)	7.66
Return on capital (%)	9.81

(Values in Cr)

Standalone Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	241.73
	9550.88
	9550.88
Total Equity	6712.07
Shares Outstanding	1322948130
Price to book ratio	2.54
Return on assets (%)	4.09
Return on capital (%)	4.97

Standalone Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	64.16
	8042.4
	8042.4
Total Equity	5261.79
Shares Outstanding	1193318500
Price to book ratio	1.55
Return on assets (%)	0.86
Return on capital (%)	1.01

Standalone Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	137.23
	7371.04
	7371.04
Total Equity	5123.12
Shares Outstanding	1185913506
Price to book ratio	0.0
Return on assets (%)	4.98
Return on capital (%)	5.86

Standalone Balance Sheet
Particulars	Mar 24 (₹ value in crores)
Cash and short-term investments	152.35
	5756.67
	5756.67
Total Equity	4100.62
Shares Outstanding	994600000
Price to book ratio	0.0
Return on assets (%)	9.92
Return on capital (%)	13.4

(Values in Cr)

Net income

Net change

Consolidated Cash Flow
Particulars	Mar 24 (₹ value in crores)
	119.8
Cash from operations	1161.38
Cash from investing	-434.01
Cash from financing	-422.36
Net change in cash	148.17
Free cash flow	1873.42

Consolidated Cash Flow
Particulars	Mar 24 (₹ value in crores)
	-160.56
Cash from operations	672.89
Cash from investing	-1338.78
Cash from financing	817.79
Net change in cash	-37.1
Free cash flow	1637.63

Consolidated Cash Flow
Particulars	Mar 24 (₹ value in crores)
	441.03
Cash from operations	935.84
Cash from investing	-1812.1
Cash from financing	794.19
Net change in cash	-251.49
Free cash flow	1825.35

Consolidated Cash Flow
Particulars	Mar 24 (₹ value in crores)
	639.68
Cash from operations	742.09
Cash from investing	-4479.93
Cash from financing	3976.83
Net change in cash	94.48
Free cash flow	1344.28

(Values in Cr)

Net income

Net change

Standalone Cash Flow
Particulars	Mar 24 (₹ value in crores)
	507.62
Cash from operations	436.1
Cash from investing	-635.52
Cash from financing	451.38
Net change in cash	174.15
Free cash flow	761.66

Standalone Cash Flow
Particulars	Mar 24 (₹ value in crores)
	123.69
Cash from operations	131.55
Cash from investing	-435.05
Cash from financing	290.12
Net change in cash	-73.41
Free cash flow	376.41

Standalone Cash Flow
Particulars	Mar 24 (₹ value in crores)
	477.41
Cash from operations	351.85
Cash from investing	-1245.61
Cash from financing	896.4
Net change in cash	-100.02
Free cash flow	584.67

Standalone Cash Flow
Particulars	Mar 24 (₹ value in crores)
	349.11
Cash from operations	130.01
Cash from investing	-4382.89
Cash from financing	4494.16
Net change in cash	145.99
Free cash flow	188.12

Company name

Price

P/E

P/B

Market cap

52 week low/high

36.46

19.6

1.99

279.41

34.11 / 77.7

119.0

15.6

1.24

1253.91

92.25 / 184.95

1549.65

25.08

4.41

125155.99

1310.05 / 1702.0

260.7

21.6

2.64

767.27

145.0 / 449.0

₹36.46

21.96

6.19

279.41

34.11 / 77.7

₹692.8

40.61

6.72

2002.93

548.05 / 861.4

₹8665.5

129.24

31.88

21663.75

5000.0 / 9199.0

₹119.0

15.45

1.22

1253.91

92.25 / 184.95

Piramal Pharma Limited technical summary

211.05-0.42

Bullish

214.4

216.7

217.2

217.7

217.6

218.6

221.0

211.6

217.3

219.7

218.7

220.6

220.9

211.7

228.5

221.3

212.97

PIVOT

First support207.7

Second support203.44

Third support₹198.17

RSI43.1

MACD-0.4%

Commodity Channel Index (CCI)₹-118.89

First resistance217.23

Second resistance222.5

Third resistance-226.76

ADX7.68

Williams % R-81.12

Date2025-04-30

Same day1047211

Week1308901

Month1500547

1 year

46.91

3 years

4.38

Price change analysis

--5.62%

Over 1 month

--6.42%

Over 3 month

--8.73%

Over 6 month

--16.41%

Over 3 year

4.38%

Over 6 year

0.0%

Piramal Pharma Limited shareholding pattern

Holding %

Public

18.77%

Promoter holdings

34.94%

FII

31.49%

DII

14.77%

Promoter shares

The Sri Krishna Trust Through Its Trustee Mr. Ajay G Piramal And Dr. (mrs.) Swati A Piramal

Ca Alchemy Investments

Hdfc Trustee Company Limited-hdfc Flexi Cap Fund

V3 Designs Llp

Prl Realtors Llp

East Bridge Capital Master Fund I Ltd

Indiahold Limited

Canara Robeco Mutual Fund A/c Canara Robeco Small Cap Fund

Piramal Welfare Trust (formerly Known As The Piramal Enterprise Executives Trust)

Semplice Corporate Solutions Private Limited (aasancorporatesolutionspvtlimited)

The Ajay G. Piramal Foundation

Mr. Anand Piramal

Anand Piramal Trust

Nandini Piramal Trust

Mr. Ajay G. Piramal

Mr. Peter Deyoung

Ms. Nandini Piramal

Master Dev Piramal Deyoung

Ms. Anya Piramal Deyoung

The Hongkong And Shanghai Banking Corp.ltd.

Prl Agastya Buildcon Pvt. Ltd

Topzone Mercantile Llp (formerly Topzone Mercantile Company Llp)

Nithyam Realty Private Limited

India Resurgence Arc Pvt. Ltd.

India Resurgence Asset Management Business Pvt. Ltd.

Piramal Trusteeship Services Pvt. Ltd.

Piramal Sons Pvt. Ltd.

The Gulita Trust

Swati Piramal Trust

Sreekovil Realty Private Limited

Anutham Realty Private Limited

Piramal Corporate & Management Services Pvt. Ltd.

Mr. Ajay G. Piramal (karta Of Ajay G. Piramal Huf)

Mrs. Lalita G. Piramal

Dr. (mrs.) Swati A. Piramal

The Swastik Safe Deposit & Investments Ltd.

The Sri Hari Trust

The Sri Govinda Trust

The Sri Gopikrishna Trust

The Piramal Art Foundation

Propiedades Realties Pvt. Ltd.

Prl Properties Llp

Prl Infraconstructions & Developers Pvt. Ltd.

Prl Developers Pvt. Ltd.

Piramal Agastya Offices Private Limited(formerly Known As Prl Agastya Pvt. Ltd.)

Piramal Water Pvt. Ltd.

Piramal Realty & Developers Pvt. Ltd. (formerly Known As Piramal Urban Transport Network Pvt Ltd)

Piramal Udgam Data Management Solutions

Piramal Systems & Technologies Pvt. Ltd.

Piramal Retail Private Limited

Piramal Residences Pvt. Ltd.

Prpl Enterprises Pvt. Ltd (formerly Known As Piramal Realty Pvt. Ltd.)

Piramal Natural Resources Pvt. Ltd.

Piramal Metals Pvt. Ltd.

Piramal Investment Advisory Services Pvt. Ltd.

Piramal International Consultants Pvt. Ltd.

Piramal Foundation

Piramal Glass Pvt. Ltd.

Piramal Fund Management Pvt. Ltd.

Piramal Foundation For Education Leadership

Piramal Estates Pvt. Ltd.

Piramal Corporate Tower Private Limited (formerly Known As Piramal Consumer Products Pvt. Ltd.)

Piramal Commercial Estates Llp

Piramal Homes Pvt. Ltd. (formerly Piramal Building Material And Cement Pvt. Ltd.)

Piramal Biotech Pvt. Ltd.

Piramal Enterprises Limited

Pel Management Sevices Pvt. Ltd.

Pel Finhold Pvt. Ltd.

Pdl Realty Pvt. Ltd.

Pce Developers Pvt. Ltd.

Nival Developers Pvt. Ltd.

Piramal Corporate Services Private Limited

Montane Ventures Pvt. Ltd.

Kaivalya Education Foundation

Indiaventure Advisors Pvt. Ltd.

Glider Buildcon Realtors Pvt. Ltd.

Alpex Infraconstructions Pvt. Ltd.

About Piramal Pharma Limited

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands. Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions. In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL). In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA). In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Enterprises Limited, Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to Company, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of the Company) into Company; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL became effective from August 18, 2022. In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023. In FY24, Company launched 27 new products and 24 new SKUs .

Parent Organisation

Piramal Ajay G

NSE Symbol

PPLPHARMA

Founded

2020

View more stocks

ONYX BIOTEC LIMITED

₹57.1

4.75%

BLUE JET HEALTHCARE LTD

₹711.15

3.75%

AMI ORGANICS LIMITED

₹1130.6

3.69%

ORTIN GLOBAL LIMITED

₹10.85

3.04%

GLAXOSMITHKLINE PHARMA LT

₹2964.6

2.15%

AMRUTAJAN HEALTH LTD

₹694.3

2.08%

INDOCO REMEDIES LTD.

₹230.6

1.72%

J B CHEMICALS AND PHARMA

₹1612.4

1.69%

AUROBINDO PHARMA LTD

₹1229.1

1.61%

SUN PHARMACEUTICAL IND L

₹1832.3

1.48%

Popular stocks

Rail Vikas Nigam

Suzlon Energy

NHPC

Yes Bank

TATA Motors

BHEL

HDFC Bank

State Bank of India

TATA Power

TATA Steel

NBCC India

Infosys India

Adani Power

IFCI

Coal India

OLA Electric

Frequently asked questions

What is share price of PIRAMAL PHARMA LIMITED?

As of Apr 30 2025 03:30 PM, at Apr 30 2025 03:30 PM, the PIRAMAL PHARMA LIMITED share price stands at Rs.211.05.

What is the market cap of PIRAMAL PHARMA LIMITED?

As of Apr 30 2025 03:30 PM, the market cap of PIRAMAL PHARMA LIMITED stands at Rs.27920.82 Cr.

What is the PE and PB ratio of PIRAMAL PHARMA LIMITED?

The PE and PB ratios of PIRAMAL PHARMA LIMITED is 40.74 ratio and 52.94 ratio as of Apr 30 2025 03:30 PM.

What is the 52 week high and low of PIRAMAL PHARMA LIMITED?

The 52 week high and low of PIRAMAL PHARMA LIMITED is Rs.307.9 and Rs.136.1 as of Apr 30 2025 03:30 PM.

How can I buy PIRAMAL PHARMA LIMITED share?

You can easily buy PIRAMAL PHARMA LIMITED shares on the Bajaj Broking platform by opening a Demat account and verifying your KYC documents online. There are no account opening charges for a Demat account with Bajaj Broking.

Show More Text Show Less Text

How to Buy Shares

Jan 30, 2025

Share Market Timings in India

May 15, 2023

What is Trading

Mar 25, 2025

What is Demat Account: Meaning, Types & Benefits

May 25, 2021

Features and benefits of Demat Account

How to open a Demat and Trading account with us

Stock market basics for beginners

Features and Benefits of a Trading account

Different types of Demat accounts

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."

**Disclaimer: For Bajaj Financial Securities Limited

Investments in securities market are subject to market risk, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. All leveraged intraday positions will be squared off the same day. There is no restriction on withdrawal of unutilised margin amount. Trade Recommendations are research-calls provided under the SEBI Research Analyst guidelines. Visit https://www.bajajbroking.in/disclaimer for complete disclaimer.

Securities market Products/services are made available only at the discretion of BFSL and subject to the individual contractual terms and conditions of the respective Securities market products/services. You shall be the sole owner of any decision to invest in any BFSL's Securities market products/services.

Securities market products/services may be withdrawn or amended at any time by BFSL without notice and your recourse in such case would be directly to reach out BFSL at connect@bajajfinserv.in or 1800 833 8888.

400

PIRAMAL PHARMA LIMITED

Piramal Pharma Limited stock performance

209.26

216.37

136.1

307.9

212.0

211.96

3050996.0

6439.12

254.35

169.56

Piramal Pharma Limited fundamentals

Piramal Pharma Limited financials

Jun 24

Particulars

202412 (₹ value in crores)

Revenue

Operating expense

Net income

Net profit margin

Earnings per share

EBITDA

Effective tax rate

Particulars

202409 (₹ value in crores)

Revenue

Operating expense

Net income

Net profit margin

Earnings per share

EBITDA